⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALT News
Altimmune, Inc. Common Stock
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
globenewswire.com
ALT
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
prnewswire.com
ALT
ALTIMMUNE (NASDAQ: ALT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
prnewswire.com
ALT
Investors in Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT
prnewswire.com
ALT
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
prnewswire.com
ALT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
prnewswire.com
ALT
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
prnewswire.com
ALT
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
prnewswire.com
ALT
INVESTOR ALERT: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
prnewswire.com
ALT
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
ALT